Schizotypal Personality Disorder Clinical Trial
— ESTS-RCTOfficial title:
A Confirmatory Randomized Controlled Trial Comparing Evolutionary Systems Therapy for Schizotypal Personality Disorder With Cognitive Behavioral Therapy
This study aims at replicating existing preliminary evidence about the effectiveness of Evolutionary Systems Therapy for Schizotypy (ESTS). The present randomized controlled trial (RCT) will compare ESTS with Cognitive Behavioral Therapy (CBT) in treating Schizotypal Personality Disorder (SPD). The main questions our RCT aims to answer are: 1. Is ESTS more effective than CBT in treating SPD? 2. Is ESTS more feasible than CBT in treating SPD? 38 patients diagnosed with SPD will be recruited and randomly allocated to either the experimental group (i.e. ESTS) or the control group (CBT). Primary outcome will be reduction in general symptomatology, whereas secondary outcomes will be changes in target mechanisms (self-criticism and metacognition) and remission from diagnosis.
Status | Recruiting |
Enrollment | 28 |
Est. completion date | January 1, 2025 |
Est. primary completion date | November 1, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Diagnosis of Schizotypal Personality Disorder at SCID-5-AMPD Module III - Age 18 or older - Being capable of reading and signing the inform consent form in Italian - Being capable of attending a talk therapy in Italian Exclusion Criteria: - Being diagnosed with schizophrenia spectrum disorders or other psychosis disorder - Being diagnosed with neurodevelopmental or neurological disorders - Being diagnosed with bipolar disorder - Being under any psychological or pharmacological treatment |
Country | Name | City | State |
---|---|---|---|
Italy | Centro di Psicologia e Psicoterapia Tages Onlus - Firenze | Firenze | FI |
Lead Sponsor | Collaborator |
---|---|
Tages Onlus |
Italy,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in general symptomatology | Change in the total score of Symptom Checklist-90-R (SCL-90-R) between two measurements | 2 measurements: one at baseline assessment; one at final assessment | |
Secondary | Change in metacognition | Change in total score of Metacognition Assessment Scale - Abbreviated (MAS-A) between two measurements | 2 measurements: one at baseline assessment (once the intervention starts); one at final assessment (6 months after, that is after weekly scheduled 24 sessions) | |
Secondary | Change in critical beliefs about self | Change in the Hated-self scale of The Forms of Self-Criticizing/attacking and Self-reassuring Scale (FSCRS) between two measurements | 2 measurements: one at baseline assessment (once the intervention starts); one at final assessment (6 months after, that is after weekly scheduled 24 sessions) | |
Secondary | Change in critical beliefs about others | Change in Socially prescribed perfectionism scale of Multidimensional Perfectionism Scale (MPS) between two measurements | 2 measurements: one at baseline assessment (once the intervention starts); one at final assessment (6 months after, that is after weekly scheduled 24 sessions) | |
Secondary | Change in schizotypal traits 1 | Change in Psychoticism scale of Personality Inventory for DSM-5 (PID-5) between two measurements | 2 measurements: one at baseline assessment (once the intervention starts); one at final assessment (6 months after, that is after weekly scheduled 24 sessions) | |
Secondary | Change in schizotypal traits 2 | Change in Detachment scale of Personality Inventory for DSM-5 (PID-5) between two measurements | 2 measurements: one at baseline assessment (once the intervention starts); one at final assessment (6 months after, that is after weekly scheduled 24 sessions) | |
Secondary | Change in remission from primary diagnosis | Change in Diagnosis of Schizotypal Personality Disorders trough Structured Clinical Interview for the DSM-5 Alternative Model for Personality Disorders (SCID-5-AMPD) Module III between two measurements | 2 measurements: one at baseline assessment (once the intervention starts); one at final assessment (6 months after, that is after weekly scheduled 24 sessions) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT02149823 -
Examining Dose-Related Effects of Oxytocin on Social Cognition Across Populations
|
Phase 1 | |
Terminated |
NCT00353379 -
Pharmacology of Cognition in Schizotypal Personality Disorder
|
Phase 4 | |
Recruiting |
NCT00252044 -
Pergolide for Cognitive Symptoms in Schizotypal Personality Disorder
|
N/A | |
Completed |
NCT00158028 -
Risperidone in the Treatment of Psychotic-like and Deficit Symptoms of Schizotypal Personality Disorder
|
N/A | |
Completed |
NCT02800681 -
Psychopathological Differences Between Asperger Syndrome and Schizotypal Disorder in an Adult Sample
|
||
Completed |
NCT02524899 -
CRT-Guanfacine for SPD
|
Phase 2 | |
Recruiting |
NCT01466205 -
Clinical Testing of a D1 Agonist for Cognitive Enhancement in Schizotypal Personality Disorder
|
Phase 2 | |
Completed |
NCT02535156 -
Schizotypal Personality Disorder Risperidone
|
Phase 1/Phase 2 | |
Completed |
NCT04764708 -
Compassion and Metacognition in Schizotypal Personality
|
N/A | |
Completed |
NCT02507206 -
A D1 Agonist For Working Memory
|
Phase 2 |